- Home
- BCDA vs KXIN Comparison
BCDA vs KXIN Comparison
Compare BCDA & KXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- KXIN
- Stock Information
- Founded
- BCDA N/A
- KXIN 2015
- Country
- BCDA United States
- KXIN China
- Employees
- BCDA N/A
- KXIN N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- KXIN Retail-Auto Dealers and Gas Stations
- Sector
- BCDA Health Care
- KXIN Consumer Discretionary
- Exchange
- BCDA Nasdaq
- KXIN Nasdaq
- Market Cap
- BCDA 7.9M
- KXIN 10.5M
- IPO Year
- BCDA N/A
- KXIN N/A
- Fundamental
- Price
- BCDA $2.68
- KXIN $0.17
- Analyst Decision
- BCDA Strong Buy
- KXIN
- Analyst Count
- BCDA 1
- KXIN 0
- Target Price
- BCDA $25.00
- KXIN N/A
- AVG Volume (30 Days)
- BCDA 73.1K
- KXIN 90.7M
- Earning Date
- BCDA 11-06-2024
- KXIN 01-01-0001
- Dividend Yield
- BCDA N/A
- KXIN N/A
- EPS Growth
- BCDA N/A
- KXIN N/A
- EPS
- BCDA N/A
- KXIN N/A
- Revenue
- BCDA $428,000.00
- KXIN $12,679,000.00
- Revenue This Year
- BCDA $6.92
- KXIN N/A
- Revenue Next Year
- BCDA N/A
- KXIN N/A
- P/E Ratio
- BCDA N/A
- KXIN N/A
- Revenue Growth
- BCDA 0.71
- KXIN N/A
- 52 Week Low
- BCDA $1.96
- KXIN $0.06
- 52 Week High
- BCDA $23.25
- KXIN $3.55
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- KXIN 49.77
- Support Level
- BCDA $2.39
- KXIN $0.15
- Resistance Level
- BCDA $2.90
- KXIN $0.19
- Average True Range (ATR)
- BCDA 0.18
- KXIN 0.08
- MACD
- BCDA -0.00
- KXIN -0.01
- Stochastic Oscillator
- BCDA 53.70
- KXIN 6.47
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company primarily generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.